McKesson Corporation released its 2025 Corporate Responsibility Report on October 29, 2024, detailing the company’s progress toward its environmental, social, and governance (ESG) goals for the previous fiscal year. The report highlights advancements in carbon emission reductions, workforce diversity, and the expansion of health equity initiatives across its global supply chain.
Progress Toward Net-Zero Carbon Emissions
McKesson is working to reduce its environmental footprint by focusing on energy efficiency and sustainable logistics. According to the 2025 Corporate Responsibility Report, the company achieved a 25% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to its 2019 baseline.
The company’s strategy involves transitioning its fleet to lower-emission vehicles and increasing the use of renewable energy across its distribution centers. McKesson has committed to reaching net-zero carbon emissions across its operations by 2050. These efforts align with the Science Based Targets initiative (SBTi), a framework that helps corporations set emissions reduction goals consistent with the Paris Agreement.
Advancing Health Equity and Access
A core component of McKesson’s social impact strategy is the focus on health equity. The company identifies disparities in care as a significant hurdle in the pharmaceutical supply chain and has implemented programs to address these gaps.
In the 2025 report, McKesson detailed its support for community-based organizations that provide resources to underserved populations. This includes investments in programs that improve access to specialty medications and oncology care. By partnering with independent pharmacies and health systems, the company aims to ensure that patients in rural or economically disadvantaged areas receive consistent access to essential medical supplies.
Workforce Diversity and Corporate Governance
McKesson’s report also outlines its internal metrics regarding human capital. As of the end of the 2024 fiscal year, women represented 46% of the company’s global workforce, with 40% of its board of directors identifying as women.
The company tracks these metrics to ensure that its leadership reflects its diverse patient and customer base. McKesson’s governance practices are overseen by the board’s Governance Committee, which monitors the integration of ESG targets into executive compensation structures. This linkage ensures that corporate leadership remains accountable for meeting sustainability and social impact objectives.
Key Performance Indicators for Fiscal Year 2024
The following table summarizes key metrics as reported by McKesson in its 2025 document:
| Metric | Status/Result |
|---|---|
| Scope 1 & 2 Emissions | 25% reduction (vs 2019) |
| Global Workforce (Women) | 46% |
| Board Diversity (Women) | 40% |
| Net-Zero Goal | By 2050 |
Future Outlook on Sustainability
McKesson’s leadership indicates that the next phase of its sustainability strategy will focus on supply chain transparency. This involves working more closely with pharmaceutical manufacturers to ensure that environmental standards are maintained upstream. The company intends to continue reporting its progress annually, providing stakeholders with verified data on its transition to more sustainable, equitable business practices.
Related reading